- Home
- URGN vs EBS Comparison
URGN vs EBS Comparison
Compare URGN & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- EBS
- Stock Information
- Founded
- URGN 2004
- EBS 1998
- Country
- URGN United States
- EBS United States
- Employees
- URGN N/A
- EBS N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- URGN Health Care
- EBS Health Care
- Exchange
- URGN Nasdaq
- EBS Nasdaq
- Market Cap
- URGN 463.2M
- EBS 393.9M
- IPO Year
- URGN 2017
- EBS 2006
- Fundamental
- Price
- URGN $4.24
- EBS $6.32
- Analyst Decision
- URGN Strong Buy
- EBS Strong Buy
- Analyst Count
- URGN 8
- EBS 3
- Target Price
- URGN $27.92
- EBS $14.33
- AVG Volume (30 Days)
- URGN 2.4M
- EBS 1.4M
- Earning Date
- URGN 05-12-2025
- EBS 05-07-2025
- Dividend Yield
- URGN N/A
- EBS N/A
- EPS Growth
- URGN N/A
- EBS N/A
- EPS
- URGN N/A
- EBS N/A
- Revenue
- URGN $91,871,000.00
- EBS $965,400,000.00
- Revenue This Year
- URGN $35.06
- EBS N/A
- Revenue Next Year
- URGN $112.94
- EBS $16.07
- P/E Ratio
- URGN N/A
- EBS N/A
- Revenue Growth
- URGN 8.98
- EBS N/A
- 52 Week Low
- URGN $3.42
- EBS $4.02
- 52 Week High
- URGN $20.70
- EBS $15.10
- Technical
- Relative Strength Index (RSI)
- URGN 27.72
- EBS 55.78
- Support Level
- URGN $3.71
- EBS $6.13
- Resistance Level
- URGN $4.25
- EBS $6.68
- Average True Range (ATR)
- URGN 0.91
- EBS 0.38
- MACD
- URGN -0.45
- EBS 0.01
- Stochastic Oscillator
- URGN 9.87
- EBS 59.06
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.